Chief Business Officer
Paula has led strategy and operations for more than 15 programs, advancing them through meaningful milestones ranging from discovery to clinical development and approvals to launches. She spent most of her career at Biogen in roles of increasing responsibility across new product planning, program management, and franchise management, culminating as senior vice president of the rare disease group. In that role, she managed a portfolio of clinical and commercial assets across hemophilia, spinal muscular atrophy, and other rare genetic diseases with annual revenues over $750 million. More recently, Paula was the chief operating officer of the gene therapy company Decibel Therapeutics. Previously, she was a board member of the gene therapy company Nightstar Therapeutics until its acquisition by Biogen for $800 million. Paula is a current board member of Prothena. She received a B.A. from Amherst College and an M.B.A. from Harvard University.